IgA antiphospholipid antibodies are an independent risk factor for thromboses

Abstract

Antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin and anti-β₂-glycoprotein I antibodies, mostly IgG isotype) are strong risk factors for thrombosis. Because a paucity of information on IgA isotype exists in the literature, we retrospectively evaluated the thrombotic significance of IgA antiphospholipid antibodies. We included 472 patients with clinical information on thrombotic events and complete laboratory work-up for antiphospholipid antibodies syndrome. Odds ratios (OR) of various antiphospholipid antibodies for thrombosis were calculated by univariate and multivariate analyses. Lupus anticoagulant alone was detected in 57 (12%) patients, ELISA-based antibodies (IgG, IgM, IgA) against cardiolipin, phosphatidylserine or β₂-glycoprotein-I alone were detected in 131 (28%) patients, whereas 80 (17%) patients had both. Antibody isotype distribution was IgG 32%, IgM 60% and IgA 56%. Univariate analysis showed a statistically significant risk of thrombosis in patients with elevated titres of IgA of any ELISA-based antiphospholipid antibodies (OR 1.77). Stepwise logistic regression (multivariate) analysis identified elevated titres of any ELISA-based IgA antiphospholipid antibodies as an independent risk factor for thrombosis (OR 1.6) in the entire cohort, and in the subgroup of patients without concurrent presence of lupus anticoagulant (OR 1.8). IgA antiphospholipid antibodies appear to be a significant independent risk factor for thrombosis, thereby meriting evaluation in patients with unexpected thrombosis.

Keywords

antiphospholipid antibodies antiphospholipid syndrome IgA lupus anticoagulant

Get full access to this article

View all access options for this article.

References

1 Bick RL . Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost 2001; 7: 241–258.

2 Triplett DA . Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126: 1424–1429.

3 Thiagarajan P Shapiro SS . Lupus anticoagulants and antiphospholipid antibodies. Hematol Oncol Clin North Am 1998; 12: 1167–1192.

4 Pengo V Thiagarajan P Shapiro SS Heine MJ . Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 69–76.

5 Harris EN Gharavi AE Loizou S . Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol 1985; 16: 1–6.

6 Bonomini M Dottori S Amoroso L Arduini A Sirolli V . Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 2: 1275–1281.

7 Barna LK Triplett DA Foster WM Gaddis ML . A study of relationships among anti-phosphatidylserine and anticardiolipin antibodies, the lupus anticoagulant and clinical complications. Lupus 1994; 3: 357.

8 Jansen NL Snell JR Moy JN . Myocardial infarction as the presenting manifestation of systemic lupus erythematosus with antiphosphatidylserine antibodies. Ann Allergy Asthma Immunol 1996; 76: 266–268.

9 Kandiah DA Krilis SA . Beta 2-glycoprotein I. Lupus 1994; 3: 207–212.

10.

10 Galli M Comfurius P Maassen C . Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547.

11.

11 Matsuura E Igarashi Y Fujimoto M . Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885–3891.

12.

12 Roubey RA . Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444–1454.

13.

13 Tsutsumi A Matsuura E Ichikawa K . Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1466–1474.

14.

14 Wilson WA Gharavi AE Koike T . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–1311.

15.

15 Miyakis S Lockshin MD Atsumi T . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

16.

16 de Laat HB Derksen RH Urbanus RT Roest M de Groot PG . beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598–3602.

17.

17 Galli M Luciani D Bertolini G Barbui T . Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717–2723.

18.

18 Samarkos M Asherson RA Loizou S . The clinical significance of IgA antiphospholipid antibodies. J Rheumatol 2001; 28: 694–697.

19.

19 Galeazzi M Sebastiani GD Tincani A . HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2000; 9: 47–55.

20.

20 Selva-O'Callaghan A Ordi-Ros J Monegal-Ferran F Martinez N Cortes-Hernandez F Vilardell-Tarres M . IgA anticardiolipin antibodies – relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998; 79: 282–285.

21.

21 Molina JF Gutierrez-Urena S Molina J . Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 291–296.

22.

22 Wong KL Liu HW Ho K Chan K Wong R . Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991; 18: 1187–1192.

23.

23 Cucurull E Gharavi AE Diri E Mendez E Kapoor D Espinoza LR . IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999; 318: 55–60.

24.

24 Escalante A Brey RL Mitchell BD Dreiner U . Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995; 98: 559–565.

25.

25 Loizou S Cofiner C Weetman AP Walport MJ . Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol 1992; 90: 434–439.

26.

26 Samarkos M Davies KA Gordon C Loizou S . Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006; 25: 199–204.

27.

27 Tsutsumi A Matsuura E Ichikawa K Fujisaku A Mukai M Koike T . IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 74–78.

28.

28 Lee RM Branch DW Silver RM . Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001; 185: 748–753.

29.

29 Fanopoulos D Teodorescu MR Varga J Teodorescu M . High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol 1998; 25: 675–680.

30.

30 Greco TP Amos MD Conti-Kelly AM Naranjo JD Ijdo JW . Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus 2000; 9: 33–41.

31.

31 Lakos G Kiss E Regeczy N . Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999; 117: 574–579.

32.

32 de Groot PG Derksen RH . Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005; 3: 1854–1860.

33.

33 Pierangeli SS Liu XW Barker JH Anderson G Harris EN . Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74: 1361–1367.